Targeted protein contrast agents, methods of making, and uses thereof
Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
1. A protein contrast agent comprising:
a parvalbumin polypeptide, wherein the parvalbumin polypeptide has the amino acid sequence comprising SEQ ID NO: 10, wherein the parvalbumin polypeptide contains a paramagnetic metal binding site consisting of one or more amino acid residues of SEQ ID NO: 10, and wherein the protein contrast agent further comprises a C—X—C chemokine receptor type 4 (CXCR-4)-targeting moiety directly fused or indirectly linked via a peptide linker to a terminus of the parvalbumin polypeptide.
2. The protein contrast agent of claim 1 , wherein the CXCR-4-targeting moiety is directly fused or indirectly linked via a peptide linker to the C terminus of the parvalbumin polypeptide.
3. The protein contrast agent of claim 1 , further comprising a paramagnetic ion, wherein the paramagnetic ion is directly bound to at least one amino acid of the parvalbumin polypeptide.
4. The protein contrast agent of claim 3 , wherein the paramagnetic ion is Gd 3+ .
5. The protein contrast agent of claim 1 , wherein the protein contrast agent is PEGylated.
6. The protein contrast agent of claim 1 , wherein the CXCR4-targeting moiety has an amino acid sequence selected from SEQ ID NOs: 36-53.
7. A pharmaceutical composition comprising:
the protein contrast agent according to claim 1 ; and
a pharmaceutically acceptable carrier.
8. A method of generating a magnetic resonance image of fibrosis or cancer in a subject, the method comprising:
administering an amount of the protein contrast agent according to claim 1 or a pharmaceutical formulation thereof to a subject; and
imaging at least a portion of the subject using magnetic resonance imaging.